首页> 美国卫生研究院文献>other >Identifying a Highly-Aggressive DCIS Subgroup by Studying Intra-Individual DCIS Heterogeneity among Invasive Breast Cancer Patients
【2h】

Identifying a Highly-Aggressive DCIS Subgroup by Studying Intra-Individual DCIS Heterogeneity among Invasive Breast Cancer Patients

机译:通过研究浸润性乳腺癌患者的个体内DCIS异质性确定高度侵袭性的DCIS亚组

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The heterogeneity among multiple ductal carcinoma in situ (DCIS) lesions within the same patient also diagnosed with invasive ductal carcinoma (IDC) has not been well evaluated, leaving research implications of intra-individual DCIS heterogeneity yet to be explored. In this study formalin-fixed paraffin embedded sections from 36 patients concurrently diagnosed with DCIS and IDC were evaluated by immunohistochemistry. Ten DCIS lesions from each patient were then randomly selected and scored. Our results showed that expression of PR, HER2, Ki-67, and p16 varied significantly within DCIS lesions from a single patient (P<0.05 for PR; P<1×10−8 for HER2, Ki-67 and p16). In addition, seventy-two percent of the individuals had heterogeneous expression of at least 2/6 markers. Importantly, by evaluating the expression of promising DCIS risk biomarkers (Ki-67, p53 and p16) among different DCIS subgroups classified by comparing DCIS molecular subtypes with those of adjacent normal terminal duct lobular units (TDLU) and IDC, our results suggest the existence of a highly-aggressive DCIS subgroup, which had the same molecular subtype as the adjacent IDC but not the same subtype as the adjacent normal TDLU. By using a systematic approach, our results clearly demonstrate that intra-individual heterogeneity in DCIS is very common in patients concurrently diagnosed with IDC. Our novel findings of a DCIS subpopulation with aggressive characteristics will provide a new paradigm for mechanistic studies of breast tumor progression and also have broad implications for prevention research as heterogeneous pre-invasive lesions are present in many other cancer types.
机译:同一患者中也被诊断为浸润性导管癌(IDC)的多个导管原位癌(DCIS)病变之间的异质性尚未得到很好的评估,因此个体内DCIS异质性的研究意义尚待探索。在这项研究中,通过免疫组织化学评估了36例同时诊断为DCIS和IDC的患者的福尔马林固定石蜡包埋切片。然后随机选择每位患者的十个DCIS病变并评分。我们的结果表明,单例患者的DCIS病变中PR,HER2,Ki-67和p16的表达差异显着(PR <0.05; HER2,P <1×10 -8 -67和p16)。另外,百分之七十二的个体具有至少2/6标记的异质表达。重要的是,通过比较DCIS分子亚型与邻近的正常末端小叶单位(TDLU)和IDC的分子类型,评估了不同DCIS亚组中有希望的DCIS危险生物标志物(Ki-67,p53和p16)的表达,我们的结果表明存在具有高度侵略性的DCIS亚组,其分子亚型与相邻的IDC相同,但与相邻的正常TDLU不相同。通过使用系统的方法,我们的结果清楚地表明,在同时诊断为IDC的患者中,DCIS的个体内异质性非常普遍。我们对具有侵略性特征的DCIS亚群的新发现将为乳腺肿瘤进展的机理研究提供新的范例,并且由于在许多其他癌症类型中均存在异质浸润前病变,因此对预防研究也具有广泛意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号